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ABSTRACT
Objective To evaluate the benefits and harms of low dose
aspirin in people with diabetes and no cardiovascular
disease.
Design Meta-analysis of randomised controlled trials.
Data sources Medline (1966-November 2008), the
Cochrane central register of controlled trials (Cochrane
Library 2008;issue 4), and reference lists of retrieved
articles.
Review methods Randomised trials of aspirin compared
withplaceboornoaspirin in peoplewithdiabetes andno
pre-existing cardiovascular disease were eligible for
inclusion. Data on major cardiovascular events (death
from cardiovascular causes, non-fatal myocardial
infarction, non-fatal stroke, and all cause mortality) were
extractedandpooledwitharandomeffectmodel.Results
are reported as relative risks with 95% confidence
intervals.
ResultsOf157studiesinthe literaturesearches,sixwere
eligible (10117 participants). When aspirin was
compared with placebo there was no statistically
significant reduction in the risk of major cardiovascular
events (five studies,9584 participants; relative risk 0.90,
95% confidence interval 0.81 to 1.00), cardiovascular
mortality(fourstudies,n=8557,0.94;0.72to1.23),orall
cause mortality (four studies, n=8557; 0.93, 0.82 to
1.05).Significantheterogeneitywasfoundintheanalysis
for myocardial infarction (I
2=62.2%; P=0.02) and stroke
(I
2=52.5%; P=0.08). Aspirin significantly reduced the risk
of myocardial infarction in men (0.57, 0.34 to 0.94) but
not in women (1.08, 0.71 to 1.65; P for
interaction=0.056). Evidence relating to harms was
inconsistent.
Conclusions A clear benefit of aspirin in the primary
prevention of major cardiovascular events in people with
diabetes remains unproved. Sex may be an important
effect modifier. Toxicity is to be explored further.
INTRODUCTION
Aspirinisrecommendedbykeyguidelineagenciesfor
the primary prevention of cardiovascular events in
people with diabetes, although with some
inconsistencies(seewebextraonbmj.com).
1-6Existing
recommendations are primarily based on indirect evi-
dence extrapolated from large trials of populations at
highriskofcardiovascularevents.
1-6Evidencesupport-
ing the efficacy of aspirin therapy in trials of only peo-
ple with diabetes is scant. A previous meta-analysis
(287trials,135000participants)ontheefficacyofanti-
platelet therapy in the prevention of major cardio-
vascular events found a clear benefit of aspirin
overall, but no statistically significant benefit in the
subgroup of only people with diabetes (nine trials,
5126 participants).
7 No significant reduction in the
risk of major cardiovascular events with low dose
aspirin compared with placebo was found in three
additional trials published after that meta-analysis.
8-10
Reactions of many in the scientific and clinical com-
munitytotheresultsofthemostrecenttrialshavebeen
mixed, some arguing for definite proof on the lack of
aspirin’s efficacy in the primary prevention of cardio-
vascular events,
11 others raising claims that data are
still inconclusive and more trials are warranted.
1213
The persisting uncertainties form the basis of our
meta-analysis of trials on the benefits and harms of
aspirin in people with diabetes and no pre-existing
cardiovascular disease.
METHODS
We included prospective, randomised, controlled,
openorblindedtrialsofparticipantswithdiabetesmel-
litus who were allocated to aspirin treatment or a con-
trol group (placebo or no treatment) for the primary
prevention of cardiovascular disease. The outcomes
of interest were all cause mortality, death from cardio-
vascular causes, non-fatal myocardial infarction, and
non-fatal stroke.
We also included data on subsetsof peoplewith dia-
beteswhowereenrolledinlargerstudiesofthegeneral
population or patients with a mixed baseline risk for
cardiovascularevents,whereaspirinwastestedagainst
placebo or no treatment.
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Using the terms diabetes mellitus and aspirin and a fil-
ter highly sensitive for randomised controlled trials
only, we searched Medline (1966-November 2008)
for trials of people with diabetes who received aspirin.
A filter for studies in humans was also used and only
trials of more than 500 participants were eligible. We
also searched the Cochrane central register of con-
trolled trials (Cochrane Library 2008;issue 4) for studies
meeting these criteria.
14 Searches were limited to pub-
lishedEnglishlanguagearticles.Referencelistsofiden-
tified trials and review articles were also searched for
additional published data on the topic.
Two authors independently reviewed results of the
search strategies and identified eligible trials; data
extraction was done independently by the same
authors using a predefined form. Information was col-
lectedonstudydesign;studysample;characteristicsof
the populations, including the proportion of men and
women enrolled; interventions; the methodological
qualityofthe trials;andthe outcomesofallcausemor-
tality, fatal or non-fatal cardiovascular and cerebro-
vascular events (defined as myocardial infarction,
stroke, or composites of these end points); any bleed-
ing, gastrointestinal bleeding, gastrointestinal symp-
toms, and incidence of cancer; withdrawals for any
reason; and proportion of patients lost to follow-up.
Discrepancies between the two reviewers were
resolved through discussion and consensus, with an
arbitrator.
Quality assessment of methods
Methodological quality of included randomised con-
trolled trials was assessed by several domains: alloca-
tion concealment (considered adequate if
randomisation method was described such that it
would not allow the investigator or participant to
know or influence the intervention group before eligi-
ble participants had entered the study; unclear if ran-
domisation was stated but no information on method
used was available; inadequate when the study used a
method of randomization such as alternation, medical
record numbers, date of birth, or unsealed envelopes,
or if any information in the study indicated that inves-
tigatorsorparticipantscouldinfluenceallocationtothe
experimental or control group); blinding of investiga-
tors, participants, and outcome assessors; use of inten-
tion to treat analysis; completeness of follow-up.
Discrepancies in data extraction between the two
reviewers were resolved by discussion and consensus,
with an arbitrator.
Statistical analysis
Wecomparedtreatmentsusingrelativeriskswith95%
confidence intervals. Heterogeneity between studies
was assessed with the Cochran’s Q and the I
2
statistics.
15 A random effects meta-analysis
16 was used
to estimate overall relative risks. The influence of
potential sources of heterogeneity on treatment effects
was explored by subgroup analysis. The following
characteristics of the population, intervention, and
methodological quality of the trials were defined a
prioriaspotentialeffectmodifiers:sex,doseofaspirin,
duration of treatment, allocation concealment, and
compliance with treatment. Analyses were carried
out using a macro routine written in SAS Language
(Release 9·1, 2002-3).
RESULTS
Of 157 potentially eligible studies identified by the
search strategy, 148 were excluded after screening of
the title and abstract because they were not rando-
mised controlled trials, they tested an intervention
other than aspirin, the control group did not involve
a placebo or no treatment, or the trial did not assess
cardiovascular events or mortality. Three additional
trials were identified by a handsearch of the bibliogra-
phyofthe remainingarticles.
81718Atotalof ninetrials,
reported in 12 publications, were assessed in full text.
Threewereexcludedastheydidnotreportdataonthe
subset of participants with diabetes.
18-20 Six rando-
mised controlled trials were finally included, totalling
10117 people with diabetes (fig 1).
8-10172122 One trial
also included a small proportion (<10%) of patients
with pre-existing established cardiovascular events.
21
Table 1 outlines the characteristics of the populations
and interventions of included randomised controlled
trials. The trials were published between 1989 and
2008, carried out in several countries, and enrolled
from 2.4%
17 to 100% of participants with
diabetes.
9102122 One study involved only men
17 and
one only women.
8 Treatment was allocated according
to a 2×2 factorial design with vitamin E in three
studies.
8922Four studies were placebo controlled and
doubleblinded.
891721Twostudies
1022wereopenlabel.
In all studies a blinded committee adjudicated out-
comes. The dose of aspirin used in the trials ranged
Potentially relevant articles identified (n=157)
Randomised controlled trials (12 publications)
including patients with diabetes (n=9)
Non-randomised controlled trials (n=57)
Tested intervention other than aspirin (n=66)
Control group was not placebo or no treatment (n=8)
Study outcomes did not include cardiovascular
  events or mortality (n=17)
Randomised controlled trials included in meta-analysis
  (6 trials, 10 117 patients)
    No of trials by outcome:
      Major cardiovascular events (5 trials, 9584 patients)
      Death from cardiovascular causes (4 trials, 8557 patients)
      All cause mortality (3 trials, 6018 patients)
      Myocardial infarction (6 trials, 10 117 patients)
      Stroke (5 trials, 9584 patients)
Randomised controlled trials
identified from reference lists (n=3)
Articles of randomised controlled trials
excluded since they did not report separate
data on participants with diabetes (n=3)
Fig 1 | Flow of trial selection process
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8 up to 650 mg
daily.
21 Follow-up ranged from 3.6
22 to 10.1 years.
8
Compliancewithtreatmentrangedbetween50%
9and
92%.
21
Quality assessment
Basedoncurrentstandards,thequalityofthe included
studies was suboptimal. Allocation concealment was
adequately described in three of the six studies
91022
and unclear in the remainder.
81721All the studies ade-
quately described blinding of outcome assessors and
five reported an intention to treat analysis.
8-102122
Only one study reported funding from industry.
22
Theproportionofparticipantswithdiabeteswithcom-
plete follow-up was reported in three trials and ranged
from 92.4% to 99.5%.
91021 For the remaining three
trials data for the whole study sample were available
but no specific information on the subset of partici-
pants with diabetes was reported.
Clinical outcomes
Major cardiovascular events
No significant reduction in the risk of major cardio-
vascular events was found with aspirin compared
with placebo or no treatment (five studies, 9584
participants, 1258 events; relative risk 0.90, 0.81 to
1.00; P=0.06). There was no significant heterogeneity
among the studies in this analysis (Q=0.94; P=0.92;
I
2=0%; fig 2). Also, there was no significant decrease
in the risk of myocardial infarction with aspirin (six
studies, 10117 participants, 834 events; 0.86, 0.61 to
1.21; P=0.37). Heterogeneity in this analysis was mod-
erate (Q=13.21; P=0.02; I
2=62.2%; fig 2), which may
be explained by the Women’s Health Study, which
enrolled women only (weight 17%), and the Physi-
cians’ Health Study, which enrolled men only (weight
12%). After excluding these studies from our analyses,
heterogeneity substantially decreased between trials
(Q=4.18; P=0.24; I
2=28.2%).
No significant reduction in the risk of stroke with
aspirin compared with placebo or no treatment was
found (five studies, 9584 participants, 382 events;
0.83, 0.60 to 1.14; P=0.25). Heterogeneity among the
trials in this analysis was moderate (Q=8.43; P=0.08;
I
2=52.5%; fig 2), which may be explained by the
Women’s Health Study (weight 16%), carried out in
women only (after exclusion of the Women’s Health
Study, Q=3.33; P=0.34; I
2=9.9%).
No significant reduction was found in the risk of
death from cardiovascular causes (four studies, 8557
Table 1 |Design of trials of aspirin therapy included in meta-analysis
Features PHS 198917 ETDRS 199221 PPP 200322 WHS 20058 POPADAD 20089 JPAD 200810
Country USA USA Italy USA Scotland Japan
Type of trial Primary Mixed Primary Primary Primary Primary
Study design Randomised double
blind,placebocontrolled
trial
Randomised double
blind,placebocontrolled
trial
Randomised open trial
with 2×2 factorial design
Randomised double
blind, 2×2 factorial,
placebo controlled trial
Randomised double
blind, 2×2 factorial,
placebo controlled trial
Randomised open label,
controlled trial with
blinded end point
assessment
Patient population Healthy men Men and women with
type 1 and type 2
diabetes
Men and women aged
>50 with ≥1 risk factors
for cardiovascular
disease
Healthy women Patients aged ≥40 years
with type 1 or type 2
diabetes and an ankle
brachial pressure index
≤0.99 but no
symptomatic
cardiovascular disease
Patients with type 2
diabetes without history
of atherosclerotic disease
Aspirin dose 325 mg every other day 650 mg/day 100 mg/day 100 mg every other day 100 mg/day 81 or 100 mg per day
Primaryoutcomemeasure Cardiovascular mortality All cause mortality Composite end point of
death from
cardiovascular cause,
myocardial infarction,
stroke
Major cardiovascular
events: non-fatal
myocardial infarction,
non-fatal stroke, death
from cardiovascular
causes
Death from coronary
heart disease or stroke,
non-fatal myocardial
infarction or stroke, or
amputation above ankle
for critical limb
ischaemia, death from
coronaryheartdiseaseor
stroke
Atherosclerotic events
includingfatalornon-fatal
ischaemic heart disease,
fatal or non-fatal stroke,
and peripheral arterial
disease
No of people with
diabetes (% of sample
where appropriate)
533 (2.4) 3711 1031 1027 (2.6) 1276 2539
Durationoftherapy(years) 5 5 3.6 10.1 6.7 4.37
Completeness of follow-
up (%)
99.7* 94.7 99.3* 99.4* 99.5 92.4
Compliance with aspirin
therapy (%)
NA 91.8 71.8 NA 50 90
Men (%) 100 56.5 48.2 — 44.1 55
Women (%) — 43.5 51.8 100 55.9 45
Mean (SD) age (years) NA NA 64.3 (7.5) NA NA 65 (10)
PHS=Physicians’ Health Study; ETDRS=Early Treatment Diabetic Retinopathy Study; PPP=Primary Prevention Project; WHS=Women’s Health Study; POPADAD=Prevention Of Progression of
Arterial Disease And Diabetes; JPAD=Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes; NA=not available.
*Data refer to whole sample.
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with aspirin compared with placebo or no treatment
(fig 2). Heterogeneity was moderate in this analysis
(Q=6.92; P=0.07; I
2=56.6%). This heterogeneity may
be explained partly by the Japanese Primary Preven-
tion of Atherosclerosis with Aspirin for Diabetes
(JPAD) study (4% weight), which enrolled Japanese
patients only (after exclusion of JPAD, Q=2.50;
P=0.29; I
2=20.1%).
All cause mortality
The risk of all cause mortality showed no significant
reduction with aspirin compared with placebo or no
treatment(fourstudies,8557participants,1018events;
0.93, 0.82 to 1.05; P=0.22; fig 2). Heterogeneity was
not significant among studies in this analysis (Q=1.02;
P=0.80; I
2=0%).
Side effects: bleeding, gastrointestinal symptoms, cancer
Table 2 presents the summary estimates of the effects
of aspirin compared with placebo or no treatment on
any bleeding, gastrointestinal bleeding, gastro-
intestinal symptoms,and cancer. Therewasnostatisti-
cally significant increase in the risk of any of these
outcomeswithaspirintherapycomparedwithplacebo
or no treatment.
Investigation of sources of heterogeneity
Heterogeneity by dose of aspirin, duration of treat-
ment, compliance with treatment, and allocation con-
cealment was explored by subgroup analysis. No
evidence of effect modification was evident by any of
these covariates for any outcome except for stroke
(table 3). The risk of stroke was significantly reduced
intrialswhereanaspirindoseof100mgorlessperday
was used compared with trials where more than
100 mg/day was used (P for interaction=0.02). Simi-
larly, the risk of stroke was significantly lower with
aspirin than with placebo or no treatment in trials of
more than five years’ duration compared with trials
offiveorfeweryears’duration(Pforinteraction=0.01).
Compliancewithtreatmentwasalsoasignificanteffect
modifier (P for interaction=0.02).
We also explored heterogeneity by sex. Aspirin sig-
nificantly reduced the risk of myocardial infarction
among men by 43% (three studies, 3126 participants,
265 events; 0.57, 0.34 to 0.94; P=0.03). In contrast, no
effect of aspirin was noted among women (three stu-
dies, 3176 participants, 245 events; 1.08, 0.71 to 1.65;
P=0.71) (P for interaction by sex=0.056; fig 3).
No significant reduction in the risk of stroke with
aspirin compared with placebo or no treatment was
found in men (two studies, 2593 participants, 93
events; 1.11, 0.75 to 1.64; P=0.61) or in women (three
studies, 3176 participants, 127 events; 0.75, 0.37 to
1.53; P=0.43; fig 3) (P for interaction by sex=0.34).
DISCUSSION
A clear benefit of aspirin in the primary prevention of
major cardiovascular events or mortality in people
with diabetes could not be identified in our meta-ana-
lysis. We found no significant reduction in the risk of
major cardiac events with aspirin compared with pla-
cebo or notreatment.Confidence intervalsin thisana-
lysisargueforapotentialbenefitofaspirin,compatible
with that observed in other high risk populations, but
the benefit was small at best or trials were underpow-
ered to detect it with sufficient precision.
Wewerealsonotabletoshowasignificantreduction
in the risk of all cause mortality with aspirin compared
with placebo or no treatment. Taken together these
data indicate either low efficacy of aspirin in people
with diabetes or insufficient evidence. In many ana-
lyses there was a significant heterogeneity, explored
JPAD
10
POPADAD
9
WHS
8
PPP22
ETDRS
21
Total
0.80 (0.59 to 1.09)
0.97 (0.76 to 1.24)
0.90 (0.63 to 1.29)
0.90 (0.50 to 1.62)
0.90 (0.78 to 1.04)
0.90 (0.81 to 1.00)
68/1262
105/638
58/514
20/519
350/1856
601/4789
0.03 0.125 0.5 1 2 8
Major cardiovascular events
Favours
aspirin
Favours control
or placebo
Relative risk
(95% CI)
Relative risk
(95% CI)
Aspirin
86/1277
108/638
62/513
22/512
379/1855
657/4795
JPAD10
POPADAD
9
WHS
8
PPP22
ETDRS21
Total
0.89 (0.54 to 1.46)
0.74 (0.49 to 1.12)
0.46 (0.25 to 0.85)
0.89 (0.36 to 2.17)
1.17 (0.87 to 1.58)
0.83 (0.60 to 1.14)
12/1262
37/638
15/514
9/519
92/1856
181/4789
32/1277
50/638
31/513
10/512
78/1855
201/4795
JPAD10
POPADAD
9
WHS8
PPP22
ETDRS
21
PHS
17
Total
0.87 (0.40 to 1.87)
1.10 (0.83 to 1.45)
1.48 (0.88 to 2.49)
0.49 (0.17 to 1.43)
0.82 (0.69 to 0.98)
0.40 (0.20 to 0.79)
0.86 (0.61 to 1.21)
28/1262
90/638
36/514
5/519
241/1856
11/275
395/5064
Myocardial infarction
14/1277
82/638
24/513
10/512
283/1855
26/258
439/5053
Control or
placebo
No of events/No in group
JPAD
10
POPADAD
9
PPP22
ETDRS
21
Total
0.10 (0.01 to 0.79)
1.23 (0.80 to 1.89)
1.23 (0.49 to 3.10)
0.87 (0.73 to 1.04)
0.94 (0.72 to 1.23)
1/1262
43/638
10/519
244/1856
298/4275
10/1277
35/638
8/512
275/1855
328/4282
Stroke
Death from cardiovascular causes
JPAD10
POPADAD
9
PPP22
ETDRS21
Total
0.90 (0.57 to 1.14)
0.93 (0.72 to 1.21)
1.23 (0.69 to 2.19)
0.91 (0.78 to 1.06)
0.93 (0.82 to 1.05)
34/1262
94/638
25/519
340/1856
493/4275
38/1277
101/638
20/512
366/1855
525/4282
All cause mortality
Fig 2 | Effect of aspirin therapy on primary prevention of major cardiovascular events,
myocardial infarction, stroke, death from cardiovascular causes, and all cause mortality in
participants with diabetes. JPAD=Japanese Primary Prevention of Atherosclerosis with Aspirin
for Diabetes; POPADAD=Prevention Of Progression of Arterial Disease And Diabetes;
WHS=Women’sH e a l t hS t u d y ;P P P =Primary Prevention Project; ETDRS=Early Treatment Diabetic
Retinopathy Study. Number in group have been reported as provided by trialists or estimated
from any available data in the publications
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cardial infarction and stroke) based on selective expo-
sures. Subgroupanalysisby sex confirmedthat aspirin
significantly reduced the risk of myocardial infarction
in men by 43%, whereas no benefit was found in
women.Therewasnostatisticallysignificantreduction
in the risk of stroke with aspirin in men and in women,
but there were opposite trends across these two sub-
groups—that is, an increased risk in men and a
decreased risk in women. Finally, we found no signifi-
cant increase in the risk of bleeding and cancer with
aspirin compared with placebo or no treatment.
Comparison with existing data
Ourdataarecoherentwithapreviousmeta-analysison
antiplatelettherapyforthepreventionofmajorcardio-
vascular events, showing a clear benefit for the overall
population (>140000 people, 22% risk reduction), but
no statistically significant benefit in the subgroup of
people with diabetes (n=5000, 7% risk reduction).
7
The potential reasons for lower efficacy of aspirin in
people with diabetes compared with other high risk
populations have been explored.
23 An increasing
amountofdatasuggestthatfactorsspecifictodiabetes,
including hyperglycaemia, hyperinsulinaemia,
increasedoxidativestress,andadvancedglycosylation
end products, may up-regulate humoral, cellular
inflammatory, and thrombogenic reactions thereby
playing a part in atherothrombosis.
24 It is plausible
that the clinical failure of aspirin in diabetes might be
attributedtomechanismsunrelatedtotheprimarybio-
chemical effect of aspirin on its main pharmacological
targets—that is, synthesis of thromboxane A2 and pla-
telet activation.
24 These findings support the view that
that people with diabetes may not simply be a sub-
group of patients at high risk of cardiovascular events
butaseparateentity,withadditionalfactorsplayingan
important part in determining the efficacy of treat-
ment.
One possibility is that the trials lacked power to
detect an effect in people with diabetes if it exists. The
results of a recently published collaborative meta-ana-
lysis by the Antithrombotic Trialists’ Collaboration
argue in that direction, suggesting a limited efficacy
of aspirin in primary prevention in people without
diabetes.
25
A differential effect of aspirin in men and women
was also described in a previous meta-analysis of pri-
mary prevention trials
26 but not confirmed in the
recent Antithrombotic Trialists’ Collaboration meta-
analysis of both primary and secondary prevention
trials analysed separately.
25 An effect was evident in
all participants enrolled in the Women’s Health
Study.
8 It remains to be established whether a true dif-
ferential “district” effect exists in men and women,
caused by mechanisms still to be elucidated, or that
the effect is simply the result of a play of chance or a
type II statistical error or lack of power.
Strengths and limitations of the meta-analysis
This is the first and largest meta-analysis of trials of
aspirin in only people with diabetes (>10000, twice
that of previously published data).
7 A strength of this
investigation is that it represents a comprehensive
review, based on a predefined study protocol and
rigid inclusion criteria for randomised trials only, and
deriving froma comprehensive search ofMedline and
the Cochrane central register of controlled trials. We
evaluatedtheefficacyofaspirinonawiderangeofout-
comes, including for the first time deaths from cardio-
vascular events and all cause mortality. The Early
Treatment Diabetic Retinopathy Study (ETDRS), the
largest study included in our meta-analysis, involved a
small proportion of people with previous cardio-
vascular events, which could not be extrapolated and
excluded from the primary analysis. The overall
resultswerenotmateriallyaffectedbyasensitivityana-
lysisexcludingthisstudyfromouranalysis(non-differ-
ential effect modification). We also could not include
some data of trials that enrolled people with diabetes
where separate results for this subgroup were not
available.
1920 Data extraction, data analysis, and qual-
ityassessments ofthemethodsweredoneby twoinde-
pendent investigators, and consistency was checked
with an arbitrator. The main weakness of this study
was the paucity of high quality randomised trials. A
possible explanation for some of our findings may be
the lack of adequate power in existing trials to detect
effects of aspirin, either because the efficacy of aspirin
was moderate to low in itself or because diabetic status
was an effect modifier.
In addition, we had concerns with the methodologi-
calqualityoftheexistingtrials.Halfofthestudieseval-
uated failed to specify whether randomisation
allocationwasconcealedandsomewererelativelyout-
dated and hardly applicable in current practice, where
patternsforthemanagementofcardiovascularriskfac-
tors in diabetes have changed. We also could not
explore the incremental benefit of aspirin over and
above other cointerventions, including statins, angio-
tensin converting enzyme inhibitors, and strict meta-
bolic control.
Heterogeneitybetweentrialswasfoundinsomeana-
lyses, which most likely reflects a sex interaction, but
other causes of heterogeneity could not be explored
owing to the scarcity of data. These issues reduce the
strengthoftheconclusionsthathavebeendrawninthis
review.
Table 2 |Comparative risk of developing drug related side effects with aspirin compared with
placebo or no treatment
Side effect
Nooftrialsreporting
outcome No of patients Relative risk (95% CI)
Any bleeding 3 7281 2.50 (0.76 to 8.21)
Gastrointestinal bleeding 3 4846 2.11 (0.64 to 6.95)
Gastrointestinal symptoms* 2 3815 5.09 (0.08 to 314.39)
Cancer 2 2307 0.84 (0.62 to 1.14)
*As generically reported by authors.
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Taken together, our findings do not support strong
recommendationstouseaspirinintheprimarypreven-
tion of cardiovascular events in all people with dia-
betes. A decision should still be taken on an
individual patient basis, after careful evaluation of a
trade-off between benefits and harms, particularly the
risk of major bleeding. Although not confirmed in
trials of only people with diabetes, several studies in
the general population have shown an absolute excess
of about one to two major bleeding complications for
every1000peopletreatedwithlowdosesofaspirinfor
oneyear.Theriskofbleedingincreasessharplyinpeo-
ple aged over 70.
27 The fact that our meta-analysis
couldnotconfirmthisintrialsofaspirininonlypeople
with diabetes is possibly due to the trials themselves
being underpowered to detect this relatively rare
event. From recent studies it can be estimated that the
incidence of major cardiovascular events in people
with diabetes and without previous cardiovascular
events is between 10 and 20 per 1000 person
years.
28-31Assumingarelativeriskreductionassociated
with aspirin treatment of about 10%, as suggested by
our meta-analysis, 1000 people need to be treated for
one year to prevent one or two major cardiovascular
events. Therefore the expected benefits might not
exceed the risk of major bleedings, particularly
among people at low cardiovascular risk (that is,
<20% over 10 years), or among older patients
(>70 years) at high risk of bleeding.
Implications for research
Two trials, A Study of Cardiovascular Events in Dia-
betes (ASCEND, International Standard Randomised
Table 3 |Subgroup analysis of sources of variability for outcomes analysed. Values are relative risks (95% confidence intervals) and number of studies
Variable
Major
cardio-
vascular
events P value*
Myocardial
infarction P value* Stroke P value*
Death from
cardio-
vascular
causes P value*
Total
mortality P value*
Aspirin dose:
≤100 mg/day 0.91 (0.78 to
1.07); n=4
0.90
1.08 (0.71 to
1.65); n=4
0.13
0.71 (0.53 to
0.94); n=4
0.02
0.76 (0.24 to
2.46); n=3
0.90
0.98 (0.77 to
1.24); n=2
0.62
>100 mg/day 0.90 (0.78 to
1.04); n=1
0.66 (0.40 to
1.07); n=2
1.17 (0.87 to
1.58); n=1
0.87 (0.16 to
4.86); n=1
0.91 (0.78 to
1.06); n=1
Duration of
therapy:
≤5 years 0.88 (0.77 to
1.00); n=3
0.45
0.72 (0.48 to
1.07); n=4
0.13
1.07 (0.84 to
1.37); n=3
0.01
0.87 (0.73 to
1.03); n=3
0.14
0.93 (0.80 to
1.07); n=2
0.99
>5 years 0.96 (0.79 to
1.17); n=2
1.17 (0.72 to
1.91); n=2
0.60 (0.42 to
0.87); n=2
1.23 (0.80 to
1.89); n=1
0.93 (0.72 to
1.21); n=1
Compliance:
<90% 0.98 (0.79 to
1.21); n=2
0.72
0.77 (0.31 to
1.92); n=2
0.91
0.74 (0.49 to
1.12); n=2
0.02
1.23 (0.83 to
1.82); n=2
0.10
0.98 (0.77 to
1.24); n=2
0.62
≥90% 0.88 (0.77 to
1.01); n=2
0.99 (0.42 to
2.37); n=2
1.09 (0.84 to
1.41); n=2
0.86 (0.72 to
1.02); n=2
0.91 (0.78 to
1.06); n=1
Allocation
concealment:
Adequate 0.92 (0.77 to
1.09); n=3
0.88
0.92 (0.49 to
1.74); n=3
0.78
0.81 (0.48 to
1.35); n=3
0.99
0.76 (0.24 to
2.46); n=3
0.90
0.98 (0.77 to
1.24); n=2
0.62
Unclear 0.90 (0.79 to
1.03); n=2
0.82 (0.47 to
1.42); n=3
0.81 (0.46 to
1.43); n=2
0.87 (0.16 to
4.86); n=1
0.91 (0.78 to
1.06); n=1
*For interaction.
PPP
22
ETDRS21
PHS
17
Total
0.38 (0.10 to 1.43)
0.74 (0.59 to 0.94)
0.40 (0.20 to 0.79)
0.57 (0.34 to 0.94)
3/246
89/1031
11/275
103/1552
Relative risk
(95% CI)
Relative risk
(95% CI)
Aspirin
8/251
128/1065
26/258
162/1574
Myocardial infarction
Men
WHS
8
PPP22
ETDRS
21
Total
1.48 (0.88 to 2.49)
0.96 (0.14 to 6.74)
0.91 (0.70 to 1.18)
1.08 (0.71 to 1.65)
36/514
2/273
81/825
119/1612
24/513
2/261
100/790
126/1564
Women
PPP
22
ETDRS21
Total
2.04 (0.38 to 11.04)
1.07 (0.71 to 1.61)
1.11 (0.75 to 1.64)
4/246
45/1031
49/1277
0.03 0.125 0.5 1 2 8
Favours
aspirin
Favours control
or placebo
2/251
42/1065
44/1316
Stroke
Men
WHS
8
PPP22
ETDRS21
Total
0.46 (0.25 to 0.85)
0.60 (0.20 to 1.80)
1.31 (0.83 to 2.08)
0.75 (0.37 to 1.53)
15/514
5/273
38/825
58/1612
31/513
8/261
30/790
69/1564
Women
Control or
placebo
No of events/No in group
Fig 3 | Effect of aspirin therapy on primary prevention of myocardial infarction and stroke
among men and women with diabetes. PPP=Primary Prevention Project; ETDRS=Early
Treatment Diabetic Retinopathy Study; PHS=Physicians’ Health Study; WHS=Women’sH e a l t h
Study. Number in group have been reported as provided by trialists or estimated from any
available data in the publications
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page 6 of 8 BMJ | ONLINE FIRST | bmj.comControlled Trial Number ISRCTN60635500) and the
Aspirin and Simvastatin Combination for Cardio-
vascular Events Prevention Trial in Diabetes
(ACCEPT-D, Current Controlled Trials
ISRCTN48110081),
32 are ongoing and will enrol
more than 15000 participants. These will help clarify
the role of aspirin in the primary prevention of cardio-
vascular disease in people with diabetes and may be
pooled with existing data. The large number of events
and participants will allow adequately powered sub-
group analyses for specific populations such as elderly
patients, women, or people with different severity of
diabetes. Meanwhile, a better understanding of the
pathophysiological mechanisms involved in the
response of platelets to aspirin may also contribute to
the identification of those who are more likely to ben-
efit from antiplatelet treatment. Whether additional
factors,suchaspoormetaboliccontrol,degreeofinsu-
lin resistance, or duration of diabetes could play an
important part in modulating platelet response to
aspirin remains a key priority for our future research
agenda in diabetes and cardiovascular diseases.
Conclusion
Taken together our findings contrast with prevailing
beliefs and existing summaries of evidence and guide-
lines based on trials done in populations at higher risk
ofcardiacevents.Wecannotrecommendusingaspirin
in the primary prevention of cardiovascular events in
all patients with diabetes without additional evidence
and contend that there is a strong case for awaiting the
results of the ASCEND and ACCEPT-D trials before
policy making in this incompletely explored area.
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